TNF and plasma cell myeloma: The mechanism of action of lenalidomide in MM is not well understood but may relate to tumor necrosis factor (TNF)-alpha inhibition, downregulation of proinflammatory cytokines, direct cytotoxic effects on myeloma cells, and antiangiogenic activity.